Exposure-Overall Survival Analysis for Quizartinib in Newly Diagnosed Patients with FMS- Like Tyrosine Kinase 3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukemia

ACoP16 (Oct 2025), Poster: S-075
Smania G, Glatard A, Vaddady P, Nakayama S, Inoue H, Mezzalana E, Simonsson USH, Abutarif M, Zheng M.
ConferenceOncologyPharmacometricsProgram strategies and efficiencies

Pharmetheus Affiliates

Portrait-of-Giovanni-Smania_Pharmetheus-1
Principal Director, MIDD Consultant

Giovanni Smania

See bio
Portrait-of-Anais-Glatard_Pharmetheus
Senior Director, MIDD Consultant

Anaïs Glatard

See bio
Portrait-of-Ulrika-Simonsson-Pharmetheus-1
Principal Director, MIDD Consultant & Senior Expert

Ulrika Simonsson

See bio
Portrait-of-Enrica-Mezzalana_Pharmetheus-1
Senior Director, MIDD Consultant

Enrica Mezzalana

See bio
Portrait-of-Christina-Pentafragka_Pharmetheus
Director, Quality Control & Medical Writing Consultant

Christina Pentafragka

See bio